In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kids’ Cosmetics With Talc Would Require Asbestos-Free Verification Or Warnings Under Dingell Bill

Executive Summary

Rep. Debbie Dingell, D-Mich., is taking another swing at legislation to require cancer warnings on talc-containing cosmetics marketed to children if they have not been determined asbestos-free via transmission electron microscopy to FDA’s satisfaction.

You may also be interested in...



Sen. Murray ‘Watching Closely’ For US FDA To Implement, Enforce Cosmetics Regulatory Reform

Senate HELP chair Patty Murray says she will ensure FDA implements cosmetics reform correctly and “effectively” uses enforcement tools. EWG exec says previous standards didn’t address “chronic harm caused by a known carcinogen like benzene.”

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

FDA Final Report: Asbestos Detected In 17% Of Talc-Containing Cosmetics, Including Products Previously Under Suspicion

NGOs including the Environmental Working Group maintain that the FDA’s testing results released on 9 March, showing traces of asbestos in nine out of 52 talc-containing cosmetics, signal a need for congressional action to tighten industry oversight. The FDA says the findings are not necessarily representative of the overall marketplace, with further talc testing planned for 2020.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148642

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel